Not long ago, I got the joy and despair of viewing many documents that were

initially not to be seen, by order of the Department of Justice, yet found their way on
various locations on the internet- specifically, the website:
www.furiousseasons.com. The documents are, or were, in fact, evidence against Eli
Lilly entirely representing their decade of deception promoting and over-medicating
others with their drug called Zyprexa, which is in a class of medications called
atypical anti-psychotics. While a new a new molecular entity by definition, this new
class called atypical antipsychotics in fact is chemically similar to the older and
typical anti-psychotics that existed, such as Haldol, which were available over 50
years ago. In many ways, the older antipsychotics are safer as well as being similar
in efficacy compared with the atypicals such as Zyprexa. Perhaps this is why Eli
Lilly did the things they did because they knew Zyprexa caused perhaps more harm
than good for those who took the medication. Of the several available atypical anti-
psychotics now available, Zyprexa and Clozaril, which was the first atypical anti-
psychotic, are believed to have the most toxic adverse events to those who take
these two in this class of medications.

Launched in 1996, Eli Lilly did not appear to consider the evidence regarding the
adverse effects that may occur to those who take this drug, yet it is believed that
there was reason to state by Lilly that there should be caution regarding the use of
Zyprexa in those patients prescribed this drug. With the belief that the maker of
Zyprexa is and will be exonerated from any responsibility related to this drug, the
promotional campaign was implemented, and has continued ever since. Evidence
of this is a warning letter received by Lilly by the FDA as a warning due to the false
and misleading claims Lilly was making about Zyprexa less than 2 months after this
drug was approved by the FDA.

At the time Zyprexa was granted approval for marketing, the medication was
indicated only for schizophrenia and mania that exists in those with bipolar disorder.
Schizophrenia has been defined as a disease that causes the sufferer to deviate
from true reality, along with visual and auditory hallucinations. Bipolar disorder is
another mental disorder where the victim alternates from states of heightened
neurokinetics to periods of what can be brutal depression for the sufferer.

Eli Lilly, known in recent years by many for their focus on marketing over science or
research, greatly desired and hoped that Zyprexa would be a welcome blockbuster
for them, which is a medication that exceeds a billion dollars a year in sales as a
minimum. And Eli Lilly appeared to have constructed the obedient and manipulated
sales force presumed to be a necessity for this monetary goal to occur without
interference. Yet in actuality, they created a sales force to break federal law from at
least the years of 1999 to 2003.
A note about pharmaceutical promotion: pharmaceutical representatives overall
are attractive and young individuals with little if any medical knowledge or training,
but are determined to have charming personalities along with a perception of
obedience related to the pharmaceutical culture, and this is all Eli Lilly in particular
wanted from the members of their sales force. The sales vocation is normally
associated to contain members with a high affinity for money, it is believed, so
corruptive acts such as off label promotion or overt kickbacks is not typically a
consideration of such people, overall, as history has shown. Therefore, if Eli Lilly’s
sales representatives who happen to be instructed to sell Zyprexafor dementia or
depression, the orders will likely be followed by such promoters. Or if this sales force
is instructed to pay specifically targeted doctors large amounts of money for doing
little or no work for this money given to such doctors, it still is not a problem for the
sales force to maintain their obedience to their corporate God. This is the
perception of not only myself, but many others as well. Plan of action meetings
(POAs) are meetings that are held a few times a year by sizable pharmaceutical
corporations to dispense orders to their sales representatives regarding the
promotion of their drugs.

A few years after Eli Lilly launched Zyprexa, the maker appeared, according to
documents, anxious due to their obvious disappointment regarding the initial
prediction that was speculated about the growth of this drug that was not meeting
their expectations, so they had POA meetings throughout the nation and shared
with the members of their sales force that there is fact a great benefit from a
monetary paradigm of implementing ‘seeding trials’, as they are a mechanism for
generating needed, although fabricated data void of any scientific gain of
knowledge (this will be discussed later). This amazingly was done and implemented
afterwards rather overtly. Even more unbelievable is that around this time, the
Zyprexasales force was instructed by Eli Lilly management to seek out clinical trial
sites, along with investigators for these trials. Preferred by Eli Lilly was that the
investigators had to either be Eli Lilly prescribing supporters or high volume
prescribers. This protocol described was written internally, along with the etiology
for performing these sham clinical trials. Anything in writing can be golden, from an
illegal situation such as this.

In addition to the clinical trial plan of action of no scientific benefit identified, Eli Lilly
instructed its sales force to utilize what was in fact inaccurate promotional material
that Eli Lilly gave its Zyprexasales representatives to be used on their sales calls
without exception. Even though this material was largely if not entirely false and
misleading, which was the intent of Eli Lilly, they encouraged their hired promoters
that such material was entirely accurate. To further saturate and corrupt the
Zyprexa sales force, they were coerced to blunt assertively what are at this time
widely recognized adverse effects of this medication, such as massive weight gain,
along with glucose and lipid abnormalities- all of which are dangerous to the user of
this medication.
The corrosive promotion of Zyprexa by Eli Lilly continued as this dangerous medical
corporation continued their efforts by intentionally altering certain Zyprexa articles
by essentially rewriting them, followed by being reviewed internally and not
externally by those who are called, 'regulators'. The purpose was to stimulate what
Eli Lilly believed was clearly absent, which was much needed commercial interest
related to Zyprexa. It unfortunately worked to a noticeable degree. This is
according to what appear to be internal documents from Eli Lilly.

Then it came time to essentially buy benign support groups, if not create what are
essentially front groups, in hopes that this would improve the growth of Zyprexa.
One example is that Eli Lilly paid the American Diabetes Association for their
assistance in obtaining endocrinologist consultants, which is a medical specialty
that treats, among other things, diabetes. To reduce any possibility of an
unexpected contingency doing this, they went ahead and hired a good sized team
of diabetes educators. In 1999, Eli Lilly altered a Zyprexa report that originally
illustrated the glucose problem with the medication, and did so with deliberate
intent and reckless disregard for others. Eventually, the American Diabetes
Association became quite the critic of Eli Lilly because of their harmful behavior
regarding Zyprexa.

A speculative thought regarding the freedom if not acceptance for this type of
promotional behavior: there exists amazing alliances between Eli Lilly and the Bush
administration have existed as well. George H.W. Bush became an Eli Lilly director
after leaving the CIA and lobbied to infect third world countries with Lilly
medications. He also did his best to maximize tax breaks further for this industry
that now employs both himself and his political affiliation. In fact, many members of
this administration have some connection with Eli Lilly. It seems to be a revolving
door issue once again. One could speculate that the Zyprexa campaign continued
for so long because of the relationships the maker of the drug had and has with
other powerful people.

The next related psychotic tactic (pun somewhat intended) Eli Lilly created was an
advisory board paid well by this company to focus on the progressing concerns of
Zyprexa. This tactic did work briefly, but did not change the view of the drug by the
medical community in any way perceptually regarding their embellished drug.

Understandably, the health care professionals in the medical community began to

get vexed and irritated by Eli Lilly’s deceptive and overtly destructive promotional
tactics regarding Zyprexa- which included the company’s own speakers that were
utilized in the past expressing concerns overtly. Such events materializing resulted
in many ways Eli Lilly being ostracized was because of their disregard for those they
are obligated to serve in the medical community, which are those in need of
restoration of their health.

Perhaps most disturbing and harmful was the Eli Lilly's intentional holding of crucial
safety information related to Zyprexa even before the drug was even approved. For
example, Eli Lilly’s Zyprexa representatives were instructed without doubt to
neutralize the legitimate concerns doctors may have about Zyprexa, if not outright
fear regarding this deadly drug they now perceived as being a clear reality. The
representatives were in agreement of continuing to dodge or neutralize legitimate
concerns about Zyprexa, with the promise of Eli Lilly’s management team to fill their
wallets more if they maintain obedience regarding this directive that caused harm in
the form of such physiological disorders as metabolic syndrome associated with
Zyprexa, yet the sales force still denied the association due to the insistence of their
employer. Essentially, the Zyprexa representatives with Eli Lilly were trained,
perhaps aggressively, to disarm negative perceptions about Zyprexa, even though
these perceptions continuously proved to be valid. This deeply troubled many
Zyprexa representatives, as at this point they were aware of the dangers of the drug
they were promoting, yet likely continued to do so in order to maintain employment.

Also, and of no great surprise, off label promotion with Zyprexa if not other products
by Eli Lilly was a norm within the organization and certainly encouraged by Eli Lilly's
management team. Encouraging doctors to prescribe Zyprexa for unapproved FDA
indications are an example. Amazingly, reflecting back on the behavioral flaws by Eli
Lilly for quite some time, they did not alter their method of business even though
there was a strong perception regarding this company being both aggressive and
greedy, and likely criminal in the way they chose to conduct their business. And
depression was not the only off label claim with Zyprexa. Eli Lilly considered such
criminal acts as off label promotion as ‘redefining the market’. This is yet another
example of their absurdity. The overt demonstration of profits over patients is
clearly absurd and inexcusable in any situation.

In the year 2000, Eli Lilly greatly expanded what was called their long term care
sales force to increase the utilization of Zyprexa intake in the elderly to nearly 200
specialty sales representatives. This patient population prescribed Zyprexa can be
deadly- as Zyprexa is harmful to older citizens- specifically pneumonia and eventual
premature death result from Zyprexaintake in this patient population. The intent
was to promote Zyprexa for those certain elderly patients with dementia and
Alzheimer’s disease, as a set of symptoms are thought to occur in such patients
called, “Sunshiner’ssyndrome- which includes elevated agitation and confusion in
such patients in the evening hours primarily. The syndrome is vague and non-
specific with unknown etiology, yet the intent was to sedate such patients with
Zyprexafor this syndrome. Furthermore, the purpose was to have Zyprexato be
used in these patients to sedate them, a process known as 'snowing'. As a result,
each long term care Lilly sales representative increased revenues for their employer
more than other sales representatives in different divisions within the organization.

Yet in the year 2002, Eli Lilly was having financial disappointments, which again did
not shock many. So to stay in form, they went on a mission to develop speakers to
align with them and to not educate others, but to pacify other doctors in hopes that
their problems with Zyprexa would disappear. After the speaker episode, Eli Lilly had
the audacity to claim that Zyprexa was indeed the best in the class of atypical
antipsychotics. Such a statement appears psychotic, to say the least. And now the
market for atypicals is about 5 billion a year, so there seemed to be no end as to
what Eli Lilly might try next. Also in this year our FDA called Eli Lilly ‘a sponsor’. I
find that a bit disturbing. As disturbing as the covert meetings Eli Lilly had with the
FDA as well.

As the new millennium progressed over the next few years, lawsuits became a
concern for Eli Lilly regarding Zyprexa. Doing what any responsible corporate entity
would most certainly do, the upper management of Eli Lilly had the audacity to
blame the media for the way they handled their drug Zyprexa. Around this time, Eli
Lilly needed and did hire a public relations firm because of their image crisis that
was likely well-deserved. About this same time, Eli Lilly implemented a nationwide
program entitled, “Operation: Restore Confidence”. I’m not sure how a fully rational
and conscious group of Eli Lilly people could create something so ridiculous and
unrealistic considering what has materialized due to their crimes. Equally deviating
from reality of Eli Lilly’s behavior is that they actually thought they could increase
Zyprexa growth by hammering home astronomical efficacy of Zyprexa and continue
on the path they have created.

Another failure to add to what has been annotated so far was when Eli Lilly hired an
organization called Lifespan Marketing, who colluded with Eli Lilly to create a brand
new market establishing Zyprexaas the standard of care. Maybe Eli Lilly needs to
adopt a standard of care for itself. This, it is understood, was largely ineffective.

At least one human insider within Eli Lilly wanted to let everyone know he did not,
nor will he ever forget his experience as a Zyprexa representative with Eli Lilly for
years. His name is Shahram Ahari and he aligned with a non-profit advocacy group
called Pharmedoutafter this experience, which was created due to a state
settlement from another pharmaceutical company's wrongdoing. Sharam spends
his days now making others aware of things such as what you have read so far. I’ve
spoken with Shahram, and I admire his assistance with others trying to correct this
medical mess. He sacrificed much, and continues to do so.

Eli Lilly appears pathologically persistent in frightening ways: next was a national
implementation plan of action which focused on training the Zyprexa sales force to
use what was called a J.C.P. study to emphasize the numerous off label benefits of
Zyprexa. At the same time, Eli Lilly determined that primary care doctors should be
their number one Zyprexa targets for increasing the growth of their drug. With this
new focus, the sales force for Zyprexa were somehow convinced to tell doctors that
fatigue is really the only side effect that presents itself with Zyprexa use by their
patients, which of course is false. Again, citizens are overall not catatonic about
such actions if they are aware of them with understanding.
While on this off label role with Zyprexa combined with being void of fair balance
regarding presenting this drug to others, Eli Lilly attempted to revive their long term
care efforts by taking on Aricept, and Alzheimer’s drug, and encouraged others to
switch to Zyprexa. The reaction for this misbehavior was Zyprexa being removed
from Medicaid in 2004, according to documents that are authentic, and are
available to others. While Lilly filed with the FDA an indication for Alzheimer’s
disease as well as dementia, Zyprexa lacked the evidence to prove that this drug
did more good than harm for such patients.

Allan Reier was the Zyprexa product team leader at one point for this drug. He may
have developed the unbelievable strategy of visiting psychiatrists to assure them
they will not be sued if they prescribe Zyprexafor their patients. Literature and
documents prove this strategy was implemented. That in itself illustrates the
concern Lilly has about Zyprexa.

So, now we are at a point where Eli Lilly had a flash of reality and preferred no
media contact. Gosh, what a surprise. There was also the disclosure of Eli Lilly
continuing to create, if not fund, the deceptive front groups to screen others in
order to sell more Zyprexa as well.

The next tactical plan from Eli Lilly was to re-implement blunting techniques
regarding Zyprexa. My guess is that they dragged this into a week- long meeting
with their sales force. This of course included dodging concerns by doctors that they
are normally encouraged to partner with, historically. Such tactical plans of action
were associated with such clever names as, ‘Viva Zyprexa’, or Zyprexa Limitless”.
Maybe the next one will be ‘ZyprexaRevenue Regression’. Zyprexa for atrophy,
maybe?

Another tactic authorized by Eli Lilly was to use those bonafide contract research
organizations (CROs) to manufacture safety, health, and outcomes database
studies. A deceptive publication plan followed.

CROs are commercial research organizations that include often what may be
substandard research investigators to work with the sponsor of such clinical trials.
Eli Lilly, as a sponsor, has the ability to alter aspects of such trials for their own
benefit. This was done- as they still encouraged as a result children to consume
Zyprexa- near a million of them involved due to an arrangement that Zyprexa will
be promoted by Lilly’s ADD drug Strattera.

As stated earlier, previously sealed and damaging documents got exposed at the
end of 2006, and are accessible on the internet and some websites, such as
www.furiousseasons.com, which is what this article is based upon, overall, these
internal documents that appear to be authentic.

Perhaps the documents should have been exposed immediately instead of being
held from public view. Perhaps prosecutors should not keep such information from
others due to a collusive relationship with such corporations. One may only
speculate as to why this occurs.

Eli Lilly makes over 4 billion dollars a year on Zyprexa, and has made close to 40
billion dollars on their drug so far.

Eli Lilly has had to pay well over a billion dollars for Zyprexadamage to others
between 2006 and 2007. The company recently paid the largest one-time payment
to settle accusations of their wrongdoing regarding Zyprexaat nearly 1.5 billion
dollars- with pending cases involving over half of the United States. I'm sad to say
I'm unconvinced this will change their behavior regarding their tactics. Cynical,
perhaps I am. History proves this is often the case:

"We deeply regret the past actions covered by the misdemeanor plea (1.4 billion
dollar settlement with the DOJ). At Lilly, we take seriously our responsibilities to
abide by all the laws governingour business practices, and we realize that we have
a tremendous responsibility to the patients and healthcare professionals we serve.
Every day and with every interaction we strive to operate in a responsible and
compliant manner. Doing the right thing is non-negotiable at Lilly, andI remain
personally committed to all of us at Lilly maintaining the highest standards of
conduct. The company's comprehensive compliance program is an embedded part
of the company's culture. These are not just words to us- we continue to implement
a range of programs and policies to help ensure that we operate in a manner
consistent with all applicable laws and regulations. These programs apply to
allparts of our business, and all of our employees are aware of the imperative for
them to be models of compliance and of ethical behavior. ------ John C. Lechleiter,
C.E.O., Eli Lilly

Psychosis- One with a personality disorder manifested in aggressive, perverted,

criminal, or amoral behavior without empathy or remorse.

Dan Abshear

Author’s note: What has been written is based upon information and belief.